# Encompass Health Corporation  Share Price Target ‘$97.00’, now 13.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/encompass-health-corporation-share-price-target-97.00-now-13.6-upside-potential/4121161343
- Published: 2024-06-21T14:53:01+01:00
- Author: Charlotte Edwards

**Encompass Health Corporation** with ticker code (EHC) have now 10 analysts in 
total covering the stock. The consensus rating is pointing to ‘strong_buy’. The 
target price High/Low ranges between $108.00 and $94.00 with the average share target
price sitting at $97.00. (at the time of writing). Given that the stocks previous
close was at $85.36 this now indicates there is a potential upside of 13.6%. The
50 day MA is $83.99 and the 200 day moving average is $73.17. The market cap for
the company is 8.51B. The stock price for the company is currently $84.48 USD

 The potential market cap would be $9,665,760,582 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 22.12, revenue per share of $49.77
and a 7.94% return on assets.

Encompass Health Corporation is a provider of post-acute healthcare service. The
Company manages its operations through its inpatient rehabilitation segment. The
Company is the owner and operator of rehabilitation hospitals. It operates hospitals
in approximately 37 states and Puerto Rico, with concentrations in the eastern half
of the United States and Texas. The Company operates approximately 156 inpatient
rehabilitation hospitals. It provides specialized rehabilitative treatment on an
inpatient basis. The Company’s inpatient rehabilitation hospitals offer specialized
rehabilitative care across an array of diagnoses and deliver comprehensive patient
care services. It also provides rehabilitative care for patients recovering from
injury or illness, using advanced technology and treatments to maximize recovery.
Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment
that leverages technologies and advanced therapies and leads to superior outcomes.

Share on: